Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889415 | 0.88 | EGFR (0.51) | ALDH1A1MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL2574422 | 0.87 | EGFR (0.47) | ALDH1A1MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL4253328 | 0.86 | EGFR (0.46) | ALDH1A1MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL39437 | 0.85 | EGFR (0.48) | ALDH1A1MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL10044900 | 0.82 | CA12 (0.48) | ALDH1A1MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL12254515 | 0.82 | MEN1 (0.55) | MEN1KMT2AEGFRNPC1RAB9A | |
| SCHEMBL1685962 | 0.81 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL19114816 | 0.81 | MEN1 (0.60) | ALDH1A1MEN1KMT2AL3MBTL1EGFR | |
| SCHEMBL29972560 | 0.81 | EGFR (0.70) | ALDH1A1MEN1KMT2AEGFRNPC1 | |
| SCHEMBL39159 | 0.81 | EGFR (0.70) | ALDH1A1MEN1KMT2AEGFRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327464-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2017-11-16 | — | — | US | disclosed |
| US-20160158216-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2016-06-09 | — | — | US | disclosed |
| US-9233927-B2 | Crystals of laquinimod sodium and improved process for the manufacture thereof | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2016-01-12 | — | — | US | disclosed |
| US-20140271878-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327464-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | POLQ, MTX1, MTX2 | ALDH1A1 557/4885MEN1 3789/4885KMT2A 15/4885 |
| US-20140271878-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | POLQ, MTX1, TLR7 | ALDH1A1 467/4885MEN1 3589/4885KMT2A 14/4885 |
| US-20160158216-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | POLQ, MTX1, TLR7 | ALDH1A1 583/4885MEN1 3899/4885KMT2A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.